Placing of shares in Hansa Biopharma AB (SE) — SEK 864 million

Carnegie acted as sole bookrunner in the placing of 3.6 million shares in Hansa Biopharma on behalf of Nexttobe, at a price of SEK 240 per share. Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. August 2020.